{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:18:56Z","timestamp":1762492736929,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ijcha.2022.101009","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T18:53:57Z","timestamp":1648493637000},"page":"101009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical features and outcomes of patients in different age groups with non-valvular atrial fibrillation receiving oral anticoagulants"],"prefix":"10.1016","volume":"40","author":[{"given":"U Fan","family":"O","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tou Kun","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3381-3529","authenticated-orcid":false,"given":"Bishow","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Wa","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai Kit","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5567-2280","authenticated-orcid":false,"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-9166","authenticated-orcid":false,"given":"Kan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijcha.2022.101009_b0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.15420\/aer.2021.07","article-title":"The 2020 ESC Guidelines on the Diagnosis and Management of Atrial Fibrillation","volume":"10","author":"Kotalczyk","year":"2021","journal-title":"Arrhythm Electrophysiol Rev."},{"issue":"7","key":"10.1016\/j.ijcha.2022.101009_b0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005657","article-title":"Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients with Atrial Fibrillation: A Sub-Analysis from the PREFER in AF","volume":"6","author":"Patti","year":"2017","journal-title":"J Am Heart Assoc."},{"issue":"6","key":"10.1016\/j.ijcha.2022.101009_b0015","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.amjmed.2018.12.036","article-title":"Net Clinical Benefit of Non-Vitamin K Antagonist vs. Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation","volume":"132","author":"Patti","year":"2019","journal-title":"Am J Med."},{"key":"10.1016\/j.ijcha.2022.101009_b0020","first-page":"100505","article-title":"Clinical characteristics and antithrombotic prescription in elderly hospitalized atrial fibrillation patients: A cross-sectional analysis of a Swedish single-center clinical cohort","volume":"27","author":"Ehrlinder","year":"2020","journal-title":"Int J Cardiol Heart Vasc."},{"issue":"1","key":"10.1016\/j.ijcha.2022.101009_b0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mayocp.2020.08.042","article-title":"Non-Vitamin K Antagonist Oral Anticoagulants in Elderly (\u226585 years) Patients with Newly Diagnosed Atrial Fibrillation: Changing Clinical Practice and Outcomes for Stroke Prevention in a Nationwide Cohort Study","volume":"96","author":"Cheng","year":"2021","journal-title":"Mayo Clin Proc."},{"issue":"11","key":"10.1016\/j.ijcha.2022.101009_b0030","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.ijcha.2022.101009_b0035","doi-asserted-by":"crossref","unstructured":"Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","DOI":"10.1093\/eurheartj\/ehaa612"},{"issue":"1","key":"10.1016\/j.ijcha.2022.101009_b0040","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.ijcha.2022.101009_b0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejim.2020.05.001","article-title":"Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis, and meta-regression","volume":"79","author":"Sagris","year":"2020","journal-title":"Eur J Intern Med."},{"issue":"5","key":"10.1016\/j.ijcha.2022.101009_b0050","first-page":"362","article-title":"Working Group on Thrombosis of Chinese Journal of Cardiology. Chinese experts\u2019 consensus on new oral anticoagulant in the non-valvular atrial fibrillation. Chin","volume":"42","author":"Dayi","year":"2014","journal-title":"J Cardiol."},{"key":"10.1016\/j.ijcha.2022.101009_b0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amjcard.2020.12.001","article-title":"Meta-Analysis Evaluating the Efficacy and Safety of Low-Intensity Warfarin for Patients >65 Years of Age with Non-Valvular Atrial Fibrillation","volume":"142","author":"Kang","year":"2021","journal-title":"Am J Cardiol."},{"issue":"12","key":"10.1016\/j.ijcha.2022.101009_b0060","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.ijcha.2022.101009_b0065","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/joa3.12652","article-title":"2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation","volume":"37","author":"Chao","year":"2021","journal-title":"J Arrhythm."},{"issue":"4","key":"10.1016\/j.ijcha.2022.101009_b0070","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/joa3.12580","article-title":"Atrial fibrillation in the elderly population: Challenges and management considerations","volume":"37","author":"Salih","year":"2021","journal-title":"J Arrhythm."},{"issue":"3","key":"10.1016\/j.ijcha.2022.101009_b0075","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1253\/circj.CJ-19-0898","article-title":"Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients with Atrial Fibrillation in Japan- Insight from the ANAFIE (All Nippon AF In Elderly) Registry","volume":"84","author":"Hiasa","year":"2020","journal-title":"Circ J."},{"key":"10.1016\/j.ijcha.2022.101009_b0080","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/CIA.S111216","article-title":"Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians","volume":"12","author":"Foody","year":"2017","journal-title":"Clin Interv Aging."},{"issue":"22","key":"10.1016\/j.ijcha.2022.101009_b0085","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.ijcha.2022.101009_b0090","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1016\/j.ijcha.2022.101009_b0095","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"issue":"9921","key":"10.1016\/j.ijcha.2022.101009_b0100","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.ijcha.2022.101009_b0105","first-page":"56","article-title":"Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios","volume":"20","author":"Chang","year":"2018","journal-title":"Int J Cardiol Heart Vasc."},{"key":"10.1016\/j.ijcha.2022.101009_b0110","unstructured":"Boletim official de Macau. No. 41. Decreto-Lei no. 68\/89\/M. (1989, SEP 23) [EB\/OL]. Retrieved from https:\/\/images.io.gov.mo\/bo\/i\/89\/41\/dl-68-89.pdf."},{"issue":"3","key":"10.1016\/j.ijcha.2022.101009_b0115","article-title":"The Choice of Antithrombotic Therapy in a Patient with New-Onset Atrial Fibrillation and High Coronary Thrombotic risk","volume":"12","author":"Maria Chiara","year":"2019","journal-title":"J Atr Fibrillation."},{"issue":"2","key":"10.1016\/j.ijcha.2022.101009_b0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest."},{"issue":"23","key":"10.1016\/j.ijcha.2022.101009_b0125","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017024","article-title":"Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights from Get with The Guidelines-Atrial Fibrillation","volume":"9","author":"Dalgaard","year":"2020","journal-title":"J Am Heart Assoc."},{"issue":"7","key":"10.1016\/j.ijcha.2022.101009_b0130","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/jth.13697","article-title":"Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis","volume":"15","author":"Melkonian","year":"2017","journal-title":"J Thromb Haemost."},{"issue":"3","key":"10.1016\/j.ijcha.2022.101009_b0135","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/bcp.14127","article-title":"Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review","volume":"86","author":"Santos","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.ijcha.2022.101009_b0140","article-title":"Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis","volume":"12","author":"Shen","year":"2021","journal-title":"Front Pharmacol."},{"issue":"5","key":"10.1016\/j.ijcha.2022.101009_b0145","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/1074248419841634","article-title":"Prescription Patterns and Outcomes of Patients with Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis","volume":"24","author":"Kattoor","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther."},{"issue":"7","key":"10.1016\/j.ijcha.2022.101009_b0150","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.amjmed.2019.01.025","article-title":"Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation","volume":"132","author":"Arbel","year":"2019","journal-title":"Am J Med."},{"issue":"1","key":"10.1016\/j.ijcha.2022.101009_b0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99818-4","article-title":"Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation","volume":"11","author":"Gozzo","year":"2021","journal-title":"Sci Rep."},{"issue":"1","key":"10.1016\/j.ijcha.2022.101009_b0160","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/STROKEAHA.118.023093","article-title":"Outcomes After Use of Standard- and Low-Dose Non-Vitamin K Oral Anticoagulants in Asian Patients with Atrial Fibrillation","volume":"50","author":"Cho","year":"2019","journal-title":"Stroke."},{"issue":"suppl_4","key":"10.1016\/j.ijcha.2022.101009_b0165","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/europace\/eux247","article-title":"Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation","volume":"19","author":"Lee","year":"2017","journal-title":"Europace."},{"issue":"5","key":"10.1016\/j.ijcha.2022.101009_b0170","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/STROKEAHA.118.024210","article-title":"Optimal Rivaroxaban Dose in Asian Patients with Atrial Fibrillation and Normal or Mildly Impaired Renal Function","volume":"50","author":"Lee","year":"2019","journal-title":"Stroke."},{"issue":"10","key":"10.1016\/j.ijcha.2022.101009_b0175","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2019.12.060","article-title":"Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial","volume":"75","author":"Zeitouni","year":"2020","journal-title":"J Am Coll Cardiol."},{"issue":"18","key":"10.1016\/j.ijcha.2022.101009_b0180","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med."},{"issue":"9586","key":"10.1016\/j.ijcha.2022.101009_b0185","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.ijcha.2022.101009_b0190","article-title":"Safety and efficacy of Direct Oral Anticoagulants (DOACs) in very elderly patients (\u2265 85 years old) with non-valvular atrial fibrillation. The Experience of an Italian tertiary care center","author":"Rubino","year":"2021","journal-title":"Minerva Med."},{"issue":"1","key":"10.1016\/j.ijcha.2022.101009_b0195","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11239-019-01923-9","article-title":"Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study","volume":"49","author":"Russo","year":"2020","journal-title":"J Thromb Thrombolysis."},{"key":"10.1016\/j.ijcha.2022.101009_b0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ahj.2020.12.002","volume":"233","author":"Carnicelli","year":"2021","journal-title":"Am Heart J."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906722000586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906722000586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:14:20Z","timestamp":1762492460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906722000586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":40,"alternative-id":["S2352906722000586"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2022.101009","relation":{},"ISSN":["2352-9067"],"issn-type":[{"type":"print","value":"2352-9067"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features and outcomes of patients in different age groups with non-valvular atrial fibrillation receiving oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2022.101009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101009"}}